Stock BLFS BIOLIFE SOLUTIONS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioLife Solutions, Inc.

Equities

BLFS

US09062W2044

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
17.53 USD +3.97% Intraday chart for BioLife Solutions, Inc. +10.53% +7.88%
Apr. 18 BioLife Solutions Completes Divestment of Global Cooling Subsidiary MT
Apr. 18 An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. for $2.6 million. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 330.9 1,306 1,552 778.3 732 794.1 - -
Enterprise Value (EV) 1 324.5 1,215 1,552 778.3 732 794.1 794.1 794.1
P/E ratio 38.5 x 443 x -169 x -5.53 x -10.7 x -16.6 x -37.3 x 100 x
Yield - - - - - - - -
Capitalization / Revenue 12.1 x 27.1 x 13 x 4.81 x 5.11 x 7.5 x 6.27 x 5 x
EV / Revenue 12.1 x 27.1 x 13 x 4.81 x 5.11 x 7.5 x 6.27 x 5 x
EV / EBITDA 58.5 x 157 x -1,424 x 217 x -157 x -1,949 x 42.4 x 22.2 x
EV / FCF 615 x 277 x -120 x -41.2 x -38.8 x -24.1 x -52.3 x 84.1 x
FCF Yield 0.16% 0.36% -0.84% -2.42% -2.58% -4.14% -1.91% 1.19%
Price to Book 7.75 x 6.42 x 2.99 x 2.12 x 2.17 x 2.52 x 2.69 x 2.62 x
Nbr of stocks (in thousands) 20,452 32,736 41,647 42,766 45,047 45,300 - -
Reference price 2 16.18 39.89 37.27 18.20 16.25 17.53 17.53 17.53
Announcement Date 3/11/20 3/22/21 2/28/22 3/16/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 27.37 48.1 119.2 161.8 143.3 105.9 126.7 158.7
EBITDA 1 5.653 8.308 -1.09 3.589 -4.664 -0.4075 18.74 35.7
EBIT 1 1.807 -2.74 -34.88 -145.5 -70.82 -44.61 -24.06 2.696
Operating Margin 6.6% -5.7% -29.27% -89.97% -49.43% -42.13% -18.99% 1.7%
Earnings before Tax (EBT) 1 9.521 -0.597 -28.69 -144.8 -66.26 -47.72 -21.74 7.394
Net income 1 11.06 2.667 -8.383 -139.8 -66.43 -47.66 -21.59 7.394
Net margin 40.42% 5.54% -7.04% -86.43% -46.36% -45.02% -17.04% 4.66%
EPS 2 0.4200 0.0900 -0.2200 -3.290 -1.520 -1.055 -0.4700 0.1750
Free Cash Flow 1 0.538 4.719 -12.98 -18.87 -18.88 -32.9 -15.19 9.442
FCF margin 1.97% 9.81% -10.89% -11.67% -13.18% -31.08% -11.99% 5.95%
FCF Conversion (EBITDA) 9.52% 56.8% - - - - - 26.45%
FCF Conversion (Net income) 4.86% 176.94% - - - - - 127.7%
Dividend per Share - - - - - - - -
Announcement Date 3/11/20 3/22/21 2/28/22 3/16/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 33.8 37.3 36.22 40.53 40.75 44.26 37.7 39.51 33.33 32.73 26.01 24.19 26.63 28.89 27.1
EBITDA 1 -2.095 -5.471 -0.814 1.495 1.449 1.726 -1.929 -1.152 -3.108 0.691 -5.792 -0.2102 2.87 3.146 4.892
EBIT 1 -11.16 -18.18 -7.633 -76.26 -11.4 -49.27 -13.6 -15.28 -28.78 -13.16 -16.04 -11.15 -9.048 -8.414 -5
Operating Margin -33.01% -48.75% -21.07% -188.15% -27.99% -111.32% -36.08% -38.68% -86.36% -40.19% -61.66% -46.08% -33.98% -29.12% -18.45%
Earnings before Tax (EBT) 1 -4.909 -17.99 -7.665 -76.29 -10.56 -49.28 -13.62 -10.19 -29.02 -13.43 -16.23 -12.11 -10.11 -9.319 -1.84
Net income 1 0.079 -15.22 -7.066 -72.55 -9.957 -49.19 -13.71 -10.2 -29.13 -13.38 -16.25 -12.13 -10.11 -9.219 -1.84
Net margin 0.23% -40.8% -19.51% -179% -24.44% -111.14% -36.37% -25.82% -87.41% -40.89% -62.47% -50.15% -37.98% -31.91% -6.79%
EPS 2 - -0.3700 -0.1700 -1.710 -0.2300 -1.150 -0.3200 -0.2300 -0.6700 -0.3000 -0.3625 -0.2675 -0.2250 -0.2025 -0.0400
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/11/21 2/28/22 5/9/22 8/9/22 11/9/22 3/16/23 5/10/23 8/8/23 11/9/23 2/29/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position 6.45 90.5 - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 0.54 4.72 -13 -18.9 -18.9 -32.9 -15.2 9.44
ROE (net income / shareholders' equity) 17.5% 2.14% -1.75% -33.2% -12.9% -17.9% -10.6% -2.1%
ROA (Net income/ Total Assets) - 1.63% -1.51% -27.8% -10.5% -14.4% -8.3% -1.7%
Assets 1 - 163.8 554.1 502.3 633.1 331 260.1 -435
Book Value Per Share 2 2.090 6.210 12.50 8.570 7.480 6.970 6.510 6.690
Cash Flow per Share 2 0.2900 0.3100 -0.0300 -0.2000 -0.2900 -0.6800 -0.4400 0.1300
Capex 1 0.68 1.93 8.39 10.4 6.38 10.3 8.17 10.2
Capex / Sales 2.47% 4% 7.04% 6.42% 4.45% 9.7% 6.45% 6.44%
Announcement Date 3/11/20 3/22/21 2/28/22 3/16/23 2/29/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for BioLife Solutions, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
17.53 USD
Average target price
23.12 USD
Spread / Average Target
+31.92%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
BIOLIFE SOLUTIONS, INC. Stock BioLife Solutions, Inc.
+7.88% 794M
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. BLFS Stock
  4. Financials BioLife Solutions, Inc.